Common Drug Review (CDR)
On September 6, 2002, the federal, provincial and territorial Ministers of Health announced the creation of a Common Drug Review (CDR). The CDR is a single process for reviewing new drugs and providing listing recommendations to participating federal, provincial and territorial (F/P/T) drug benefit plans in Canada. All jurisdictions are participating except Quebec.
|
Health Council
The mandate of the Health Council, as described in the 2003 First Ministers' Accord on Health Care Renewal, will be "to monitor and make annual public reports on the implementation of the Accord, particularly its accountability and transparency provisions. The Health Council will publicly report through federal/provincial/territorial Ministers of Health and will include representatives of both orders of government, experts and the public. To fulfil its mandate, the Council will draw upon consultations and relevant reports, including governments' reports, the work of the Federal/Provincial/Territorial Advisory Committee on Governance and Accountability and the Canadian Institute of Health Information (CIHI)."
For additional information on the Health Council visit the following Web site.
http://www.hc-sc.gc.ca/english/media/releases/2003/2003_97bk1.htm
|
Speech from the Throne: Strengthening the Foundation for Change
The Honourable James K. Bartleman, Lieutenant Governor of Ontario, on the opening of the First Session of the Thirty-Eighth Parliament of the Province of Ontario.
November 20, 2003
ThroneSpeech112003En.pdf 0 B
|
The Romanow Report
The Commission on the Future of Health Care in Canada was established by the Prime Minister in April 2001. It's mandate was to engage Canadians in a national dialogue on the future of heath care and to make recommendations to preserve the long-term sustainability of Canada’s universally accessible, publicly funded health care system.
Included in this section are materials relating to this commission.
|
Cross-Border Internet Pharmacy
Canadian consumer groups joint position statement regarding cross-border Internet pharmacy.
April 14, 2004
CBIP Position Statement.pdf 0 B
|
Direct To Consumer Advertising (DTCA)
Direct-to-consumer (DTC) advertising of brand name prescription medicines is not currently allowed under Canada’s Food and Drug Act, except for advertising of ‘name, price and quantity’, a provision introduced in 1978 to allow comparative price advertising. In fact, the laws regulating the advertising of medications in this country were written more than 40 years ago. However, the federal government is considering legislative change, as Canadians are increasingly exposed to cross-border US media-based drug ads, web-based advertising, and indirect advertising originating in Canada. As a result, the information they receive may not apply in Canada, or the drug may not even be approved for use here. DTCA is controversial, with many claims made about both beneficial and harmful effects.
|
|
